Do not use this product without medical advice if you are pregnant. It is not known whether bifidobacterium, lactobacillus, and streptococcus passes into breast milk or if it could harm a nursing baby. Do not use this product without medical advice if you are breast-feeding a baby. Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. This is not a complete list of side effects and others may occur.
Call your doctor for medical advice about side effects. Do not use in larger or smaller amounts or for longer than recommended. Use exactly as directed on the label, or as prescribed by your doctor. Your doctor may occasionally change your dose. Mix the oral powder with cold water or a non-carbonated drink or soft food applesauce, yogurt, ice cream.
Eat or drink this mixture right away. Do not save it for later use. You may also open the capsule and sprinkle the probiotic into a cold drink or cold soft food, following the same directions for the oral powder. Call your doctor if your symptoms do not improve, or if they get worse while using bifidobacterium, lactobacillus, and streptococcus.
Store this product in the refrigerator, do not freeze. Clinical studies using VSL 3 and published in notable journals, such as Gut, Gastroenterology and the American Journal of Gastroenterology have indicated that it colonizes the GI tract with beneficial bacteria, and in doing so, forms an intestinal barrier, which may help protect the GI tract and promote the absorption of nutrients.
VSL 3 is one of the few probiotic preparations supported by Level 1 double-blind, placebo-controlled scientific data, and has been the subject of a collection of more than 80 studies that have demonstrated its efficacy, specifically in the dietary management of IBS, Ulcerative Colitis and Ileal Pouch. It is the only probiotic recognized as an effective tool in the dietary management of pouchitis by the American College of Gastroenterology2 and by the Cochrane Review3 for the treatment and prevention of pouchtis after ileal pouch-anal anastamosis for chronic ulcerative colitis.
VSL 3 products are available online at www. Dig Dis Sci. VSL 3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. Probiotics VSL 3 protect against development of visceral pain in murine model of irritable bowel syndrome.
Antinociceptive effect of VSL 3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Mol Cell Biochem. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Male accessory gland infection frequency in infertile patients with chronic microbial prostatitis and irritable bowel syndrome.
Int J Androl. Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL 3. Asian J Androl. The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. Infectious gastroenteritis and risk of developing inflammatory bowel disease.
Risk factors and gene polymorphisms of inflammatory bowel disease in population of Zhejiang, China. J Crohns Colitis. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL 3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol.
The probiotic preparation, VSL 3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. VSL 3 probiotic-mixture induces remission in patients with active ulcerative colitis.
VSL 3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol. Effect of a probiotic preparation VSL 3 on induction and maintenance of remission in children with ulcerative colitis. Probiotic preparation VSL 3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.
Probiotic mixture VSL 3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis.
The VSL 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. J Nutr. Live and heat-killed probiotic: effects on chronic experimental colitis induced by dextran sulfate sodium DSS in rats. Int J Clin Exp Med. Effects of the probiotic formulation VSL 3 on colitis in weanling rats. Defects in mucosal immunity leading to Crohn's disease.
Immunol Rev. Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol. Predictability of the postoperative course of Crohn's disease. The probiotic VSL 3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. J Immunol. Dev Comp Immunol. J Histochem Cytochem. Pharmacotherapy for acute pouchitis. Ann Pharmacother. Once daily high dose probiotic therapy VSL 3 for maintaining remission in recurrent or refractory pouchitis.
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Pardi DS. Microscopic colitis: an update. VSL 3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial.
BMJ Open Gastroenterol. Int J Colorectal Dis. Increased epithelial cell proliferation in the ileal pouch mucosa of patients with familial adenomatous polyposis. Virchows Arch. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Combination of metformin and VSL 3 additively suppresses western-style diet induced colon cancer in mice.
Eur J Pharmacol. VSL 3 can prevent ulcerative colitis-associated carcinogenesis in mice. J Gastroenterol Hepatol. Pretreatment with the probiotic VSL 3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. VSL 3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer.
Sci Rep. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. Beneficial effects of a probiotic VSL 3 on parameters of liver dysfunction in chronic liver diseases. Randomised clinical trial: The beneficial effects of VSL 3 in obese children with non-alcoholic steatohepatitis. Int J Obes Lond ; 39 — Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion.
J Biol Chem. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Stancovski I, Baltimore D. NF-kappaB activation: the I kappaB kinase revealed?
The c-Jun NH 2 -terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser J Biol Chem. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol. Probiotic antigens stimulate hepatic natural killer T cells. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome.
Am J Med Sci. VSL 3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells.
The protective effect of VSL 3 on intestinal permeability in a rat model of alcoholic intestinal injury. BMC Gastroenterol. Wiest R, Garcia-Tsao G. Bacterial translocation BT in cirrhosis.
Alteration of intestinal intraepithelial lymphocytes and increased bacterial translocation in a murine model of cirrhosis. Immunol Lett. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis. Riordan SM, Williams R. Mechanisms of hepatocyte injury, multiorgan failure, and prognostic criteria in acute liver failure.
Semin Liver Dis. Effects of the adjunctive probiotic VSL 3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int. Oral probiotic VSL 3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. The effect of short term treatment with probiotic VSL 3 on various clinical and biochemical parameters in patients with liver cirrhosis. J Physiol Pharmacol. Probiotics VSL 3 prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system.
Dhiman RK. Gut microbiota and hepatic encephalopathy. Metab Brain Dis. Linkage of gut microbiome with cognition in hepatic encephalopathy. Effect of probiotic VSL 3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial. Hepatol Res. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Eur J Gastroenterol Hepatol. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Probiotic VSL 3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.
Probiotic supplementation attenuates increases in body mass and fat mass during high-fat diet in healthy young adults. Obesity Silver Spring ; 23 — Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet.
Effect of probiotic VSL 3 and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. Mediators Inflamm. Leaky gut and diabetes mellitus: what is the link? Obes Rev. Oral probiotic administration induces interleukin production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. J Diabetes Res. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice.
ISME J. J Physiol. Use of probiotic bacteria for prevention and therapy of allergic diseases: studies in mouse model of allergic sensitization. Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy.
Mol Nutr Food Res. Cafeteria diet and probiotic therapy: cross talk among memory, neuroplasticity, serotonin receptors and gut microbiota in the rat. Mol Psychiatry. Modulation of intestinal microbiota by the probiotic VSL 3 resets brain gene expression and ameliorates the age-related deficit in LTP. J Neurosci.
Gut dysbiosis impairs recovery after spinal cord injury. J Exp Med. Human oral, gut, and plaque microbiota in patients with atherosclerosis. AMB Express. VSL 3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.
Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors.
Pediatr Clin North Am. The human milk microbiota: origin and potential roles in health and disease. Pharmacol Res. Administration of a multistrain probiotic product VSL 3 to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery.
Vaginal microbial flora and outcome of pregnancy. Arch Gynecol Obstet. Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion. BMC Microbiol. Onderdonk AB. Probiotics for women's health. Probiotic mix VSL 3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis.
Probiotics Antimicrob Proteins. Support Center Support Center. External link. Please review our privacy policy. Delia et al[ 40 ], Delia et al[ 39 ], Dubey et al[ 44 ], Frohmader et al[ 46 ], Selinger et al[ 37 ], Lacouture et al[ 47 ], Patients with advanced NSCLC treated with dacomitinib were enrolled in two cohorts cohort I: patients, including 56 in the doxycycline group, 58 in the placebo group; cohort II: 59 patients with VSL 3 plus topical alclometasone.
Bazzocchi et al[ 49 ], Kim et al[ 50 ], Kim et al[ 51 ], Twice a day 31 patients received 4 wk and 17 patients received 8 wk , the daily dose was not clear. Guandalini et al[ 53 ], Vicari et al[ 60 ], Wong et al[ 52 ], Vicari et al[ 59 ], Venturi et al[ 66 ], Tursi et al[ 70 ], Bibiloni et al[ 71 ], Soo et al[ 72 ], Sood et al[ 68 ], Huynh et al[ 74 ], One dose of VSL 3 sachet containing 4.
Miele et al[ 73 ], Weight-based dose, range: 4. Tursi et al[ 67 ], Gionchetti et al[ 91 ], Gionchetti et al[ 14 ], Mimura et al[ 90 ], Shen et al[ 93 ], Gionchetti et al[ 92 ], Loguercio et al[ ], Alisi et al[ ], Miccheli et al[ ], Gupta et al[ ], Jayakumar et al[ ], Marlicz et al[ ], Mittal et al[ ],
0コメント